IPO - unknown

Form Type: 8-K

Filing Date: 2025-01-15

Corporate Action: Ipo

Type: New

Accession Number: 000110465925003529

Filing Summary: On January 14, 2025, Anteris Technologies Global Corp. announced the partial exercise of the over-allotment option related to its initial public offering (IPO) and notified about the conclusion of the stabilization period associated with the IPO. This announcement was lodged with the Australian Securities Exchange, marking a significant development in the company's capital-raising efforts. An exhibit containing the details of the announcement has been attached as Exhibit 99.1 to this 8-K filing.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-12-10

Corporate Action: Ipo

Type: New

Accession Number: 000110465924127184

Filing Summary: Anteris Technologies Global Corp. has filed a request for acceleration of the effective date of its Registration Statement on Form S-1, seeking to have it become effective on December 12, 2024, at 4:00 p.m. Eastern Time. This action is being taken in accordance with Rule 461 under the Securities Act of 1933. The representatives of the underwriters will ensure adequate distribution of the preliminary prospectus to dealers participating in the security distribution, complying with the relevant regulations under the Securities Exchange Act of 1934. The letter is signed by representatives from TD Securities (USA) LLC, Barclays Capital Inc., and Cantor Fitzgerald & Co., all acting on behalf of the several underwriters involved.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-11-22

Corporate Action: Ipo

Type: Update

Accession Number: 000110465924122093

Filing Summary: Anteris Technologies Global Corp. responded to comments from the U.S. Securities and Exchange Commission regarding their Amendment No. 4 to Draft Registration Statement on Form S-1, filed on November 4, 2024. The Company acknowledged staff comments concerning disclosures on the convertible note facility's impact on dilution and revised relevant sections of the prospectus. Updates were provided on the status of their FIH clinical study and milestones related to upcoming presentations and trials. Furthermore, the Company disclosed significant increases in selling, general, and administrative expenses for the nine months ended September 30, 2024, detailing expansion costs related to their plans for re-domiciling, NASDAQ listing, and initial public offering. The Company emphasized readiness to resolve any outstanding issues promptly, underscoring their commitment to the IPO process.

Document Link: View Document

Form Type: DRSLTR

Filing Date: 2024-10-11

Corporate Action: Ipo

Type: Update

Accession Number: 000110465924108096

Filing Summary: Anteris Technologies Global Corp. submitted Amendment No. 2 to its Draft Registration Statement on Form S-1 on August 9, 2024, addressing comments from the SEC Staff regarding its planned pivotal clinical trial design and market opportunity details. The company acknowledged the need for more detailed disclosures on product trials and market potential. Revised sections include the prospectus summary, market analysis, risk factors, and specific details regarding agreements with third parties. Key focus was on clarifying total market opportunity estimates, revising disclosures about agreements with suppliers and research partners, and outlining patent protections related to their products. The document reflects the company’s ongoing efforts to ensure compliance with SEC queries while simultaneously preparing for its initial public offering (IPO).

Document Link: View Document